The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?

Clin Microbiol Infect. 2009 Sep;15(9):865-8. doi: 10.1111/j.1469-0691.2009.02810.x. Epub 2009 Jun 22.

Abstract

The pneumococcal antigens contained in the polysaccharide (PPV23) and conjugate (7-valent, PCV7; 13-valent, PCV13) vaccines have been chosen since they represent the serotypes that more frequently cause invasive pneumococcal disease. Whether these vaccines cover the serotypes most frequently isolated in haematology patients is unclear. The serotype distribution among Streptococcus pneumoniae in 25 consecutive pneumococcal infections that occurred over the last 3 years in two French haematology departments was investigated. The pneumococcal vaccines PCV7, PCV13 and PPV23 were found to cover 76, 84 and 92%, respectively, of the serotypes found.

MeSH terms

  • Adult
  • Aged
  • Female
  • France / epidemiology
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / immunology
  • Humans
  • Immunocompromised Host
  • Male
  • Middle Aged
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Vaccines / immunology*
  • Serotyping
  • Stem Cell Transplantation / adverse effects
  • Streptococcus pneumoniae / classification*
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Pneumococcal Vaccines